Harvard Bioscience
HBIO
100 hedge funds and large institutions have $90.7M invested in Harvard Bioscience in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 25 reducing their positions, and 10 closing their positions.
110% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 10
88% more call options, than puts
Call options by funds: $32K | Put options by funds: $17K
68% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 25
12% more funds holding
Funds holding: 89 → 100 (+11)
0.17% less ownership
Funds ownership: 7.49% → 7.32% (-0.17%)
34% less capital invested
Capital invested by funds: $138M → $90.7M (-$47.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$1.48M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.09M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$727K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$527K |
| 5 |
Millennium Management
New York
|
+$454K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2C
272 Capital
Dallas,
Texas
|
-$4.56M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$2.41M |
| 3 |
ACM
Archon Capital Management
Seattle,
Washington
|
-$1.11M |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
-$567K |
| 5 |
AE
AMH Equity
Great Neck,
New York
|
-$436K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HIM
101
Hillsdale Investment Management
Toronto,
Ontario, Canada
| – | -$112K | -2,640 | Closed |
|
|
MIM
102
MetLife Investment Management
Whippany,
New Jersey
| – | -$89.7K | -2,115 | Closed |
|
|
AIG
103
American International Group
New York
| – | -$84.7K | -1,998 | Closed |
|
104
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$70.2K | -1,656 | Closed |
|
|
OSAM
105
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | -$65.7K | -1,550 | Closed |
|
106
VOYA Investment Management
Atlanta,
Georgia
| – | -$61.5K | -1,451 | Closed |
|
|
B
107
Bailard
Foster City,
California
| – | -$56.1K | -1,323 | Closed |
|
|
MLICM
108
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$9.91K | -234 | Closed |
|
|
CWP
109
Concord Wealth Partners
Abingdon,
Virginia
| – | -$9.54K | -225 | Closed |
|
|
FCG
110
Financial Connections Group
Corte Madera,
California
| – | +$1.05K | +30 | New |
|
HBIO Hedge Fund Activity: Q2 2024 in Review
100 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2024, worth a combined $90.7M — down 34% from $138M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new HBIO positions and 10 closed out — a net gain of 11 holders — while 42 added to existing stakes and 25 trimmed.
The largest buyer was Russell Investments Group, adding an estimated $1.48M. The largest seller was 272 Capital, cutting an estimated $4.56M.
- 100 institutional investors held Harvard Bioscience (HBIO) as of Q2 2024, up from 89 in Q1 2024.
- Funds reported $90.7M of Harvard Bioscience stock for Q2 2024, down 34% quarter-over-quarter.
- 21 funds opened new Harvard Bioscience positions in Q2 2024 and 10 closed out, a net change of +11 holders.
- The largest Harvard Bioscience buyer in Q2 2024 was Russell Investments Group, an estimated $1.48M added.
- The largest Harvard Bioscience seller in Q2 2024 was 272 Capital, an estimated $4.56M sold.
Based on aggregated 13F filings for Q2 2024.